07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Integrin avβ3 (CD51/CD61)

Cancer INDICATION: Cancer In vitro and mouse studies identified a protein inhibitor of the integrin CD51/CD61 that could help treat cancer. In silico analysis of the binding interaction of CD2 analogs with CD51/CD61 and in vitro binding...
07:00 , Apr 10, 2014 |  BC Innovations  |  Cover Story

Pre-EMP-tive strike against GBM

University of California, Los Angeles researchers have treated glioblastoma in mice by inhibiting epithelial membrane protein 2.1 The findings open up a new indication for spinout Paganini Biopharma Inc., which has a mAb against the...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Company News

Tactic Pharma, Wilson Therapeutics deal

Wilson acquired Decuprate ( ATN-224) from Tactic. Wilson plans to develop the copper-specific binder for Wilson's disease, a rare autosomal recessive disorder caused by mutation in the ATP7B gene, which leads to an...
07:00 , May 29, 2008 |  BC Innovations  |  Targets & Mechanisms

Swell Effect on Glioma

Gliomas, unlike most other tumor types, grow and expand by killing off surrounding tissue, causing neurodegeneration and edema. Chemotherapy and radiotherapy attack the tumor itself, but do not address these two other effects of the...
07:00 , Apr 10, 2008 |  BC Innovations  |  Cover Story

Metastasis, Interrupted

Two studies have clarified the roles of two different proteins in metastasis, suggesting potential new therapeutic strategies to treat cancer. One study proposes agonizing the membrane protein CD151 to prevent cancer cells from mobilizing at...
07:00 , Apr 5, 2004 |  BC Week In Review  |  Clinical News

Attenuon preclinical data

In a mouse model of breast cancer, tumors in animals treated with ATN-161 regressed or grew significantly more slowly than tumors in control animals. ATN-161 significantly decreased the number of tumor metastases in the lungs,...